+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of midtreatment FDG-PET in oropharyngeal cancer



Prognostic value of midtreatment FDG-PET in oropharyngeal cancer



Head and Neck 38(10): 1472-1478



Prognostic metabolic imaging indices are needed for risk stratification for patients with locally advanced oropharyngeal cancer. We retrospectively examined pretreatment and midtreatment fluorodeoxyglucose-positron emission tomography (FDG-PET) parameters in patients with locally advanced oropharyngeal cancer who were treated with definitive chemoradiation. A total of 74 patients were evaluated. Pretreatment metabolic tumor volume (MTV) using threshold of 50% standardized uptake value (SUV) maximum (MTV50% ) was associated with progression-free survival (PFS; p = .003; hazard ratio [HR] = 1.57 per 10 cc; 95% confidence interval [CI] = 1.17-2.11) and overall survival (OS; p = .01; HR = 1.36 per 10 cc; 95% CI = 1.07-1.74). Midtreatment MTV using a threshold of SUV 2.0 (MTV2.0 ) was associated with PFS (p < .001; HR = 1.24 per 10 cc; 95% CI = 1.10-1.39) and OS (p = .009; HR = 1.21 per 10 cc; 95% CI = 1.05-1.39). Nodal total lesion glycolysis (TLG) velocity >5% decrease/week was associated with improved PFS (p = .04; HR = 0.37; 95% CI = 0.15-0.95). Metabolic response during chemoradiation is associated with survival in locally advanced oropharyngeal cancer and may aid with risk-adapting treatment. © 2016 Wiley Periodicals, Inc. Head Neck 38: First-1478, 2016.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637885

Download citation: RISBibTeXText

PMID: 27043927

DOI: 10.1002/hed.24454


Related references

Prognostic factors in oropharyngeal cancer. Cirugia Y Cirujanos 71(4): 275-278, 2003

Prognostic implications of HPV in oropharyngeal cancer. New England Journal of Medicine 363(1): 82-84, 2010

HPV and oropharyngeal cancer: etiology and prognostic importance. Seminars in Cutaneous Medicine and Surgery 34(4): 178-181, 2016

Cancer stem cell enrichment marker CD98: a prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. European Journal of Cancer 50(4): 765-773, 2014

Prognostic utility of basaloid differentiation in oropharyngeal cancer. Journal of Otolaryngology - Head and Neck Surgery 42: 57, 2014

A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer. Cancer Epidemiology 38(5): 591-598, 2015

Prognostic impact of complete remission after radical radiotherapy of oropharyngeal cancer A retrospective study of the Cancer Centre in Warsaw data, 1984-1995. European Journal of Cancer 37(Supplement 6): S107, 2001

Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear, Nose, and Throat Journal 86(8): 506-511, 2007

Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. Journal of Clinical Oncology 33(8): 836-845, 2015

Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clinical Cancer Research 10(17): 5684-5691, 2004

Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head and Neck 28(2): 107-113, 2006

A population-based study of prognostic factors in oral and oropharyngeal cancer. European Journal of Cancer. Part B, Oral Oncology 30b(6): 369-373, 1994

Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer. Laryngoscope 122 Suppl 2: S13-S33, 2012

Head and neck cancer Pretreatment and midtreatment PO2 levels. European Journal of Cancer 35(SUPPL 4): S172-S173, Sept, 1999

Response to intraarterial induction chemotherapy: a prognostic parameter in oral and oropharyngeal cancer. Head & Neck 28(8): 678-688, 2006